Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017 (2017), Article ID 5856475, 8 pages
https://doi.org/10.1155/2017/5856475
Research Article

Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

1Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Japan
2Division of General Internal Medicine 1, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Japan

Correspondence should be addressed to Masashi Shimoda

Received 20 February 2017; Revised 16 April 2017; Accepted 27 April 2017; Published 25 May 2017

Academic Editor: Kazuya Yamagata

Copyright © 2017 Masashi Shimoda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. prospective diabetes study group,” Diabetes, vol. 44, no. 11, pp. 1249–1258, 1995. View at Publisher · View at Google Scholar
  2. P. A. Halban, K. S. Polonsky, D. W. Bowden et al., “Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 6, pp. 1983–1992, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Holst, T. Vilsboll, and C. F. Deacon, “The incretin system and its role in type 2 diabetes mellitus,” Molecular and Cellular Endocrinology, vol. 297, no. 1-2, pp. 127–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Meier and M. A. Nauck, “Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?” Diabetes, vol. 59, no. 5, pp. 1117–1125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, and J. J. Meier, “Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?” Diabetologia, vol. 54, no. 1, pp. 10–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Lee, D. Yabe, K. Nohtomi et al., “Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes,” Endocrine Journal, vol. 57, no. 2, pp. 119–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Abrahamsen and E. Nishimura, “Regulation of glucagon and glucagon-like peptide-1 receptor messenger ribonucleic acid expression in cultured rat pancreatic islets by glucose, cyclic adenosine 3′,5′-monophosphate, and glucocorticoids,” Endocrinology, vol. 136, no. 4, pp. 1572–1578, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Xu, H. Kaneto, D. R. Laybutt et al., “Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes,” Diabetes, vol. 56, no. 6, pp. 1551–1558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kawashima, T. A. Matsuoka, H. Kaneto et al., “Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice,” Biochemical and Biophysical Research Communications, vol. 404, no. 1, pp. 534–540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. P. V. Hojberg, M. Zander, T. Vilsboll et al., “Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes,” Diabetologia, vol. 51, no. 4, pp. 632–640, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Paolisso, P. A. Tataranni, J. E. Foley, C. Bogardus, B. V. Howard, and E. Ravussin, “A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM,” Diabetologia, vol. 38, no. 10, pp. 1213–1217, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. McGarry and R. L. Dobbins, “Fatty acids, lipotoxicity and insulin secretion,” Diabetologia, vol. 42, no. 2, pp. 128–138, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Giacca, C. Xiao, A. I. Oprescu, A. C. Carpentier, and G. F. Lewis, “Lipid-induced pancreatic beta-cell dysfunction: focus on in vivo studies,” American Journal of Physiology. Endocrinology and Metabolism, vol. 300, no. 2, pp. E255–E262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Karpe, J. R. Dickmann, and K. N. Frayn, “Fatty acids, obesity, and insulin resistance: time for a reevaluation,” Diabetes, vol. 60, no. 10, pp. 2441–2449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Lee, H. Hirose, M. Ohneda, J. H. Johnson, J. D. McGarry, and R. H. Unger, “Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 10878–10882, 1994. View at Google Scholar
  18. Y. P. Zhou and V. E. Grill, “Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle,” The Journal of Clinical Investigation, vol. 93, no. 2, pp. 870–876, 1994. View at Publisher · View at Google Scholar
  19. S. R. Crespin, W. B. Greenough 3rd, and D. Steinberg, “Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect,” The Journal of Clinical Investigation, vol. 52, no. 8, pp. 1979–1984, 1973. View at Publisher · View at Google Scholar
  20. J. Kozawa, K. Okita, A. Imagawa et al., “Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes,” Biochemical and Biophysical Research Communications, vol. 393, no. 3, pp. 410–413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Muscelli, A. Mari, A. Casolaro et al., “Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients,” Diabetes, vol. 57, no. 5, pp. 1340–1348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. F. K. Knop, K. Aaboe, T. Vilsboll et al., “Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity,” Diabetes, Obesity and Metabolism, vol. 14, no. 6, pp. 500–510, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. F. Kang, Y. Deng, Y. Zhou et al., “Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes,” Diabetologia, vol. 56, no. 2, pp. 423–433, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. D. J. Hodson, R. K. Mitchell, E. A. Bellomo et al., “Lipotoxicity disrupts incretin-regulated human beta cell connectivity,” The Journal of Clinical Investigation, vol. 123, no. 10, pp. 4182–4194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Seino, H. Kuwata, and D. Yabe, “Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives,” Journal of Diabetes Investigation, vol. 7, Supplement 1, pp. 102–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Kanamori and I. Matsuba, “Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer,” Journal of Clinical Medicine Research, vol. 5, no. 3, pp. 217–221, 2013. View at Publisher · View at Google Scholar
  27. H. Maeda, A. Kubota, A. Kanamori, Y. Tanaka, Y. Terauchi, and I. Matsuba, “Long-term efficacy and safety of sitagliptin in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c <7%,” Journal of Endocrinological Investigation, vol. 36, no. 8, pp. 568–573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. Kahn, J. M. Lachin, B. Zinman et al., “Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT,” Diabetes, vol. 60, no. 5, pp. 1552–1560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Gallwitz, J. Guzman, F. Dotta et al., “Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial,” Lancet, vol. 379, no. 9833, pp. 2270–2278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Seck, M. Nauck, D. Sheng et al., “Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study,” International Journal of Clinical Practice, vol. 64, no. 5, pp. 562–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Gallwitz, J. Rosenstock, T. Rauch et al., “2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial,” Lancet, vol. 380, no. 9840, pp. 475–483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Allagnat, F. Alonso, D. Martin, A. Abderrahmani, G. Waeber, and J. A. Haefliger, “ICER-1gamma overexpression drives palmitate-mediated connexin36 down-regulation in insulin-secreting cells,” The Journal of Biological Chemistry, vol. 283, no. 9, pp. 5226–5234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Cigliola, V. Chellakudam, W. Arabieter, and P. Meda, “Connexins and beta-cell functions,” Diabetes Research and Clinical Practice, vol. 99, no. 3, pp. 250–259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Maeda, A. Kubota, Y. Tanaka, Y. Terauchi, and I. Matsuba, “The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 95, no. 1, pp. e20–e22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Senmaru, M. Fukui, K. Kobayashi et al., “Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations,” Journal of Diabetes Investigation, vol. 3, no. 6, pp. 498–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Bando, H. Kanehara, K. Aoki, A. Hisada, D. Toya, and N. Tanaka, “Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients,” Journal of Diabetes Investigation, vol. 3, no. 2, pp. 170–174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Iwasaki, F. Hoshian, T. Tsuji et al., “Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels,” Journal of Diabetes Investigation, vol. 3, no. 5, pp. 464–467, 2012. View at Publisher · View at Google Scholar · View at Scopus